Inhibace Plus

Cilazapril/Hydrochlorothiazide, the active ingredient in Inhibace Plus, is an ACE inhibitor and thiazide diuretic presented as an oral tablet for systemic use. It treats hypertension in adult patients. GNH USA supplies Inhibace Plus as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inhibace Plus is indicated for the management of hypertension, a condition characterized by elevated arterial pressure.

Hypertension: lowers systolic and diastolic blood pressure, reducing the risk of cardiovascular events.

Inhibace Plus may cause a range of adverse reactions.

Common Side Effects: - Dizziness or light‑headedness - Headache - Persistent dry cough - Increased urination or nocturia - Electrolyte disturbances (e.g., low potassium) - Fatigue

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Severe dehydration or hypotension - Acute kidney injury or worsening renal function - Severe electrolyte abnormalities (hyperkalemia, hyponatremia) - Blood dyscrasias (e.g., agranulocytosis) - Hepatic dysfunction or jaundice

Before initiating therapy, clinicians should consider several safety measures.

Monitor blood pressure regularly: ensure therapeutic control and detect hypotension. Assess renal function: baseline and periodic creatinine/eGFR measurements. Check serum electrolytes: especially potassium and sodium levels. Avoid use in pregnancy: drug is classified as Category D. Counsel patients on orthostatic dizziness: advise rising slowly from sitting or lying positions. Store at ambient temperature: keep in the original pack, protect from moisture.

Inhibace Plus can interact with several medicines; awareness of interaction severity guides management.

Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal impairment. - Concurrent ACE inhibitor with ARB: heightened risk of hyperkalemia and renal dysfunction. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalemia. - NSAIDs (e.g., ibuprofen): can reduce antihypertensive efficacy and impair renal function. - Lithium: risk of lithium toxicity due to reduced clearance.

Moderate Interactions (Monitor Closely): - Other thiazide diuretics or antihypertensives: may enhance blood‑pressure lowering effect. - CYP450 inhibitors (e.g., ritonavir): may increase cilazapril levels. - Antacids containing aluminum or magnesium: may decrease absorption of cilazapril. - Beta‑blockers: may mask tachycardia from hypotension. - Diuretics with glucose‑lowering agents: monitor blood glucose as hypoglycemia risk may rise.